Clinical Study of Rosiglitazone Maleate Combined with Continuous Subcutaneous Insulin of Infusion on Endothelium Dependent Vasodilation in Newly Diagnosed Type 2 Diabetes Patients

LI Xiao-ling,ZHU Lü-yun,YANG Shao-ling,HU Li-ye,SHAN Wei
2008-01-01
Abstract:Objective:To investigate the effects of Rosiglitazone maleate(Ros M)combined with continuous subcutaneous Insulin of infusion(CSII)on endothelium dependent vasodilation in newly-diagnosed type 2 diabetes mellitus(T2DM).Methods:106 newly diagnosed patients with T2DM were randomly divided into therapeutic group(CSII combined with Ros M,n=66)and control group(n=40,simple CSII).The level of blood glucose,HbAIc,endothelium-dependent dialatation(EDD),HOMR-IR,IAI,therapeutic time,amount of Insulin and weight were compared between them 2 weeks before and after treatment.Ros M was used in the therapeutic group for a 3-month follow-up.Results:Two weeks after the treatment,the BG,TG,HbA1c,HOMR-IR dropped significantly(P<0.05).EDD and IAI escalated in both groups(P<0.05),while IAI、EDD were obviously higher,HOMR-IR,therapeutic time,and amount of Insulin was relatively lower in therapeutic group than those in the control group.The 3-month follow-up study showed that the therapeutic group did not show any serious hypoglycaemia and impaired function of heard,liver and kidney.Conclusion:CSII therapy combined with Ros M can increase the IAI,improve endothelium dependent vasodilation,reduce T2DM patients' Insulin resistance,protect blood vessel endothelium function and is favorable for T2DM prognosis.
What problem does this paper attempt to address?